Exploring MAPS Phase 3 clinical MDMA trial, examining psychedelics in Europe vs. North America and investigating psychedelics for pain treatment. Read more in Issue 27 of The Psychedelics Newsletter. 

Announcing the next PSYCH Investor Summit: Research & Development, MindMed hits the NASDAQ and exploring the use of psychedelics to treat addiction. Read more in Issue 26 of The Psychedelics Newsletter. 

Rick Doblin on MAPS 35 years, the future of the psychedelics industry and kicking off the PSYCH Investor Summit: Europe & Asia. Read more in Issue 25 of The Psychedelics Newsletter.

Exploring psychedelics apps, Awakn Life Sciences’ new Digital unit and counting down to the PSYCH Investor Summit: Europe & Asia. Read more in Issue 24 of The Psychedelics Newsletter.

Exploring the potential to create ethical psychedelics companies, a DNA test to inform psychedelic therapies, and preparing for the PSYCH Investor Summit: Europe and Asia. Read more in Issue 23 of The Psychedelics Newsletter.

Four companies added to the world’s largest psychedelics exchange and adding Field Trip Health to the PSYCH Investor Summit: Europe and Asia. Learn more in Issue 22 of The Psychedelics Newsletter.

The Australian government has announced $15m of funding for psychedelic medicines in a boost to the domestic and international market. Learn more in Issue 21 of The Psychedelics Newsletter.

The first-ever ketamine-assisted psychotherapy clinic has opened in the UK while Field Trip Health has confirmed the closing of $95m of funding. All this and more in Issue 20 of The Psychedelics Newsletter.

Researchers have published the results of a global drug survey, revealing that the use of psychedelics to treat mental health conditions is increasing.

Researchers have published the results on the most comprehensive study on microdosing while European psychedelic companies have been given an edge in the international market.

The results of a study on the use of MDMA to treat alcohol addiction have been published this week, whilst reforms on the use of psychedelics continue to take shape across the US.

The PSYCH Investor Summit is now open for registration and you can apply for tickets in this week’s issue of our newsletter, which also includes the most important stories from across the industry.

The Psychedelics industry has hit a major milestone as a number of industry-leading businesses have been listed on a dedicated exchange, allowing shares to be traded freely.

PSYCH hits 25,000 subscribers to become industry’s fastest-growing newsletter while a number of major announcements on the advancement of research into psychedelic medicines have been made.

Following a breakout year for the psychedelic sector, the pharmaceutical industry is set to take on a more prominent role in the market in 2021 and beyond. Learn more and catch up with the latest investment trends and scientific findings in Issue 13 of The Psychedelics Newsletter.

The psychedelic compound known as DMT will be used in a trial to treat depression for the first time in the United Kingdom while MDMA has been proven to help people suffering from alcohol addiction. All this and more in issue 12 of the PSYCH Newsletter.

Gain access to every panel discussion from The PSYCH Symposium before time runs out and catch up on the latest news from across the international psychedelics industry in Issue 11 of The Psychedelics Newsletter, here.

The PSYCH Symposium is set to bring together leaders from across the international psychedelics industry who are set to discuss and debate the most important issues facing the sector.

Taking place 17-20 as part of Prohibition Partners LIVE, The PSYCH Symposium will bring together distinguished industry thought leaders, rising entrepreneurs and experienced policymakers.

An Oregonian Congressman supports a measure for the legalisation of psilocybin therapy and psychedelic decriminalisation awaits a response from the Canadian government.

Canada approves end-of-life psilocybin treatment for palliative patients while UK scientists and experts propose easing restrictions for medical psychedelics and Californian activists propose easing restrictions for medical psychedelics.

An attempt to block the Washington D.C. psychedelic initiative fails, therapists request approval to test psychedelics in Canada and Oregon gets set to vote on psilocybin for therapeutic use in November 2020.

Oregon psilocybin decriminalisation campaign and DC activists say they will qualify for the November ballot while the New Medical Psychedelics Working Group to lobby for ease in UK research restrictions.